The COVID-19 pandemic has had an immeasurable impact on society. While vaccines and antiviral therapies hold promise to restore some degree of normalcy to post-pandemic society, novel health interventions come with significant questions about the funding for drug development, and the ethics and implications of health policy decisions.
As the economic and societal impacts of COVID-19 continue to pervade our social discourse, an emerging question is how vaccines and antiviral therapies will be priced. More specifically, given the development costs and resource requirements, and the array of societal benefits and avoided costs, what is fair? In this Life Science Leader article, the authors apply a framework for identifying the determinants of fairness judgements when setting price to understand perceptions of fairness of prices for COVID-19 vaccines and therapies, and the drivers of these perceptions.